Vaxcyte Statistics
Share Statistics
Vaxcyte has 124.64M shares outstanding. The number of shares has increased by 28.01% in one year.
| Shares Outstanding | 124.64M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 11.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 120.32M |
| Failed to Deliver (FTD) Shares | 13.26K |
| FTD / Avg. Volume | 1.26% |
Short Selling Information
The latest short interest is 8.93M, so 7.16% of the outstanding shares have been sold short.
| Short Interest | 8.93M |
| Short % of Shares Out | 7.16% |
| Short % of Float | 7.43% |
| Short Ratio (days to cover) | 12.89 |
Valuation Ratios
The PE ratio is -15.17 and the forward PE ratio is -21.1.
| PE Ratio | -15.17 |
| Forward PE | -21.1 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 4.92 |
| P/FCF Ratio | -16.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Vaxcyte Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.54 |
| Quick Ratio | 7.54 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.57 |
| Cash Flow / Debt | -41.73 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.32% and return on capital (ROIC) is -36.86%.
| Return on Equity (ROE) | -0.32% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -36.86% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.58M |
| Employee Count | 254 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 44.88% in the last 52 weeks. The beta is 1.01, so Vaxcyte 's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | 44.88% |
| 50-Day Moving Average | 101.92 |
| 200-Day Moving Average | 84.25 |
| Relative Strength Index (RSI) | 37.54 |
| Average Volume (20 Days) | 1.06M |
Income Statement
In the last 12 months, Vaxcyte had revenue of $0 and earned -$402.27M in profits. Earnings per share was $-4.14.
| Revenue | 0 |
| Gross Profit | -75.00M |
| Operating Income | -468.04M |
| Net Income | -402.27M |
| EBITDA | -464.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -4.14 |
Balance Sheet
The company has $397.45M in cash and $29.22M in debt, giving a net cash position of $368.23M.
| Cash & Cash Equivalents | 397.45M |
| Total Debt | 29.22M |
| Net Cash | 368.23M |
| Retained Earnings | -924.39M |
| Total Assets | 3.56B |
| Working Capital | 2.09B |
Cash Flow
In the last 12 months, operating cash flow was -$296.79M and capital expenditures -$67.88M, giving a free cash flow of -$364.67M.
| Operating Cash Flow | -296.79M |
| Capital Expenditures | -67.88M |
| Free Cash Flow | -364.67M |
| FCF Per Share | -3.75 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PCVX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.72% |
| FCF Yield | -3.33% |
Analyst Forecast
The average price target for PCVX is $146.5, which is 67% higher than the current price. The consensus rating is "Buy".
| Price Target | $146.5 |
| Price Target Difference | 67% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 47.58 |
| Piotroski F-Score | 3 |